Vascular Disrupting Agent | Vascular-targeting Agent

Choose Selective VDA Inhibitors

VDA Signaling Pathway Map

VDA Products

All (3)
New VDA Products

Catalog No.	Product Name	Information	Product Use Citations
S1176	Plinabulin (NPI-2358)	Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.	J Med Chem, 2022, 65(13):9159-9173 ACS Omega, 2022, 7(25):21465-21472 J Biol Chem, 2019, 294(20):8161-8170
S1537	Vadimezan (ASA404)	Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.	Cell, 2022, 185(1):169-183.e19 Nat Immunol, 2022, 23(2):287-302 Nat Cell Biol, 2022, 24(5):766-782
S1786	Verteporfin (CL 318952)	Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.	Nat Commun, 2022, 13(1):3117 Nat Commun, 2022, 13(1):50 Redox Biol, 2022, 54:102384

Catalog No.

Product Name

Information

Product Use Citations

Product Validations

S1176

Plinabulin (NPI-2358)

Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.

J Med Chem, 2022, 65(13):9159-9173

ACS Omega, 2022, 7(25):21465-21472

J Biol Chem, 2019, 294(20):8161-8170

S1537

Vadimezan (ASA404)

Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.

Cell, 2022, 185(1):169-183.e19

Nat Immunol, 2022, 23(2):287-302

Nat Cell Biol, 2022, 24(5):766-782

S1786

Verteporfin (CL 318952)

Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

Nat Commun, 2022, 13(1):3117

Nat Commun, 2022, 13(1):50

Redox Biol, 2022, 54:102384